News & Events

• October 14, 2021
  

  Academic Innovation Leader and Experienced Scientist to Join C-Path’s PKD Consortium

  C-Path today announced it has named Sorin Fedeles, Ph.D., MBA as Executive Director of its Polycystic Kidney Disease Outcomes Consortium (PKDOC), effective October 1, 2021.

• August 21, 2020
  

  C-Path’s PKDOC and The PKD Foundation Set to Collaborate Once Again

  Polycystic Kidney Disease (PKD) is an inherited disorder in which clusters of cysts develop in the kidneys. There are more than 200,000 US cases diagnosed each year and many people with this condition have kidney failure by age 60. To meet the challenge in discovering treatments for PKD, C-Path’s Polycystic Kidney Disease Outcomes Consortium (PKDOC) is excited to announce a collaboration with The PKD Foundation, who’s mission is to fund research, advocate for patients and build a community for all impacted by PKD. The agreement renews the significant collaboration between C-Path and The PKD Foundation to facilitate existing and new mutually agreed upon programs to accelerate the pace and reduce the cost of medical product development for the diagnosis and treatment of PKD. Learn more about PKDOC.

• November 13, 2015
  

  C-Path’s Polycystic Kidney Disease Outcomes Consortium Secures EMA Qualification Opinion for Enrichment Biomarker in ADPKD

  November 13, 2015 C-Path’s Polycystic Kidney Disease Outcomes Consortium Secures EMA Qualification Opinion for Enrichment Biomarker in ADPKD TUCSON, Ariz., November 13, 2015 – The Critical Path Institute (C-Path) announced today that the European Medicines Agency (EMA) rendered a positive qualification opinion to C-Path’s Polycystic Kidney Disease Outcomes Consortium (PKDOC) for total kidney volume (TKV) as a prognostic...
• August 30, 2015
  

  Critical Path Institute’s Polycystic Kidney Disease Outcomes Consortium Secures FDA Qualification for Enrichment Biomarker in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

  August 31, 2015 Critical Path Institute’s Polycystic Kidney Disease Outcomes Consortium Secures FDA Qualification for Enrichment Biomarker in Autosomal Dominant Polycystic Kidney Disease (ADPKD) TUCSON, Ariz., August 31, 2015 – The Critical Path Institute (C-Path) announced today that the U.S. Food and Drug Administration (FDA) has issued a qualification decision in the form of a...
• June 1, 2015
  

  Critical Path Institute Secures Regulatory Support For Autosomal Dominant Polycystic Kidney Disease (ADPKD) Biomarker

  TUCSON, Ariz., June 1, 2015 — The Critical Path Institute (C-Path) announced today that the U.S. Food and Drug Administration (FDA) has issued a Letter of Support to C-Path’s Polycystic Kidney Disease Outcomes Consortium (PKDOC) for the use of total kidney volume (TKV) as a prognostic biomarker to select patients for clinical trials of new therapies for Autosomal Dominant Polycystic Kidney Disease (ADPKD).
  ADPKD is a debilitating genetic disease affecting more than 600,000 Americans and 12 million people worldwide. It is characterized by progressive enlargement of the kidneys due to the formation and growth of cysts. TKV is a measurement of the impact of ADPKD on the size of the kidneys and is believed to be predictive of a future decline in kidney function